Roche holding aktiengesellschaft

US StockHealth Care

RHHBY AI Analysis Overview

Keys for Bullish View

  • Value≥4
  • Dividend≥2

Analysis Conclusion

With insufficient quarterly financial data released by the company, we're unable to provide a rating.

RHHBY Current Performance

1.45%

Roche holding aktiengesellschaft

0.68%

Avg of Sector

0.03%

S&P500

Top 10 High Relevance to RHHBY

  • MRNA Moderna inc
    Value 3Trend 3Swing Trading 3Whale Interest 3Dividend 1
    See more

RHHBY Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Price of RHHBY